CD44 and head and neck squamous cell carcinoma: While monoclonal antibodies against specific CD44 isoforms have been tested in patients with HNSCC for potential imaging or targeting therapy against tumors [61], our data support the notion that therapeutic pharmaceuticals that target CD44 cleavage mechanisms within the stem cell compartment can impair stemness and thus hold promise for treating aggressive oral cancer.